IL159412D0 - A synergistic pharmaceutical combination for the prevention or treatment of diabetes - Google Patents

A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Info

Publication number
IL159412D0
IL159412D0 IL15941202A IL15941202A IL159412D0 IL 159412 D0 IL159412 D0 IL 159412D0 IL 15941202 A IL15941202 A IL 15941202A IL 15941202 A IL15941202 A IL 15941202A IL 159412 D0 IL159412 D0 IL 159412D0
Authority
IL
Israel
Prior art keywords
prevention
treatment
pharmaceutical combination
diabetes
synergistic pharmaceutical
Prior art date
Application number
IL15941202A
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0102982A priority Critical patent/HU0102982D0/en
Priority to HU0202204A priority patent/HU226244B1/en
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Priority to PCT/HU2002/000067 priority patent/WO2003007951A1/en
Publication of IL159412D0 publication Critical patent/IL159412D0/en

Links

Abstract

The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.
IL15941202A 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes IL159412D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (en) 2002-07-05 2002-07-05 A pharmaceutical combination for treating or preventing diabetes
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (1)

Publication Number Publication Date
IL159412D0 true IL159412D0 (en) 2004-06-01

Family

ID=26317981

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15941202A IL159412D0 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes
IL15941203A IL159412A (en) 2001-07-17 2003-12-17 Synergistic pharmaceutical combination for the prevention or treatment of diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15941203A IL159412A (en) 2001-07-17 2003-12-17 Synergistic pharmaceutical combination for the prevention or treatment of diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (en)
EP (1) EP1408966B1 (en)
JP (1) JP4598390B2 (en)
KR (1) KR100920560B1 (en)
CN (1) CN1270713C (en)
AT (1) AT386523T (en)
AU (1) AU2002354884B2 (en)
BR (1) BR0210744A (en)
CA (2) CA2682251A1 (en)
CY (1) CY1107939T1 (en)
DE (1) DE60225143T2 (en)
DK (1) DK1408966T3 (en)
ES (1) ES2300460T3 (en)
IL (2) IL159412D0 (en)
MX (1) MXPA04000324A (en)
NO (1) NO20040153L (en)
NZ (1) NZ531155A (en)
PL (1) PL205826B1 (en)
PT (1) PT1408966E (en)
RU (1) RU2311907C2 (en)
WO (1) WO2003007951A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044531A2 (en) * 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2357983T3 (en) 2006-11-02 2011-05-04 N-Gene Research Laboratories Inc. pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect.
CN101646439B (en) 2006-11-02 2011-09-07 N基因研究实验室公司 Method of reduction of overweight or obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
AU2008276842C9 (en) 2007-07-19 2014-08-21 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
CA2707484A1 (en) * 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
KR101839177B1 (en) 2011-04-13 2018-03-15 아이오니스 파마수티컬즈, 인코포레이티드 Antisense modulation of ptpib expression
HU1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HU1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (en) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 Metformin-acipimox compound sustained-release capsule and preparing method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
DK1115697T3 (en) * 1998-09-03 2004-06-07 N Gene Res Lab Inc Unsaturated hydroximic acid derivatives as PARP inhibitors

Also Published As

Publication number Publication date
AU2002354884B2 (en) 2007-10-18
AU2002354884A2 (en) 2003-03-03
PL205826B1 (en) 2010-05-31
CN1531433A (en) 2004-09-22
JP4598390B2 (en) 2010-12-15
CY1107939T1 (en) 2013-09-04
US7635674B2 (en) 2009-12-22
US20070015687A1 (en) 2007-01-18
ES2300460T3 (en) 2008-06-16
WO2003007951A1 (en) 2003-01-30
EP1408966B1 (en) 2008-02-20
US8048873B2 (en) 2011-11-01
DE60225143D1 (en) 2008-04-03
AT386523T (en) 2008-03-15
US20100048627A1 (en) 2010-02-25
DE60225143T2 (en) 2009-02-12
MXPA04000324A (en) 2004-07-23
KR100920560B1 (en) 2009-10-08
NO20040153L (en) 2004-03-16
NZ531155A (en) 2005-07-29
KR20040029371A (en) 2004-04-06
CA2682251A1 (en) 2003-01-30
EP1408966A1 (en) 2004-04-21
CA2452558C (en) 2009-12-22
CA2452558A1 (en) 2003-01-30
RU2004105149A (en) 2005-04-20
RU2311907C2 (en) 2007-12-10
CN1270713C (en) 2006-08-23
PL364662A1 (en) 2004-12-13
PT1408966E (en) 2008-05-02
DK1408966T3 (en) 2008-06-16
JP2004537550A (en) 2004-12-16
IL159412A (en) 2009-09-22
BR0210744A (en) 2004-07-20

Similar Documents

Publication Publication Date Title
TW509674B (en) N-(substituted glycyl)-2-cyanopyrrolidine derivatives
TWI284641B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
TWI230153B (en) Azetidine derivatives, their preparation and pharmaceutical compositions containing them
TW589197B (en) Stabilized antihistamine syrup
TW393469B (en) 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
TWI226329B (en) Compounds of the formula I for the treatment of ischemia, and pharmaceutical composition comprising the same
TW579378B (en) Glucopyranosyloxypyrazole derivatives, pharmaceutical compositions comprising the same and intermediates thereof
NZ505377A (en) Compositions and method for protecting skin from uv induced immunosuppression and skin damage
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
TW200422299A (en) Substituted oxazolidinones and their use
UA71912C2 (en) 3-aryl-2-hydroxypropionic acid derivative, a process for its manufacture (variants), intermediate compound, a pharmaceutical composition (variants) and a method for prevention and/or treatment of clinical conditions associated with insulin resistance
CA2457410A1 (en) Compounds effecting glucokinase
MXPA02003308A (en) Compounds for the treatment of ischemia.
TW200302088A (en) Cannabinoid receptor ligands
MXPA02002024A (en) Pharmaceutical tramadol salts.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
TWI274055B (en) Aryl-5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same
WO2002046129A3 (en) Inhibitors of histone deacetylase
ECSP045004A (en) Inhibitors 17beta-hydroxysteroid dehydrogenase type 3 for the treatment of androgen dependent diseases
WO2003002593A3 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
HU0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
MXPA04007590A (en) 2,4,6-triamino-1,3,5-triazine derivative.
NO20061657L (en) Pyrolderivater with antibacterial activity
BG105968A (en) HETEROCYCLIC-CONTAINING BIPHENYL aP2 INHIBITORS